Amano, M., Ito, M., Kimura, K., et al., 1996. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 271, 20246-9.
B?鬣khed, F., Crawford, P. A., O''Donnell, D., et al., 2007. Postnatal lymphatic partitioning from the blood vasculature in the small intestine requires fasting-induced adipose factor. Proc Natl Acad Sci. 104, 606-611.
Barbara, E. R., Nathalie, F. W., Cameron, J. W., et al., 2005. Rho and vascular disease. Atherosclerosis. 183, 1-16.
Barchowsky, A., Dudek, E. J., Treadwell, M. D., et al., 1996. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med. 21, 783-90.
Benbrahim-Tallaa, L., Waalkes, M. P., 2008. Inorganic arsenic and human prostate cancer. Environ Health Perspect. 116, 158-64.
Breslin, J. W., Yuan, S. Y., 2004. Involvement of RhoA and Rho kinase in neutrophil-stimulated endothelial hyperpermeability. Am J Physiol Heart Circ Physiol. 286, H1057-62.
Brouwer, O. F., Onkenhout, W., Edelbroek, P. M., et al., 1992. Increased neurotoxicity of arsenic in methylenetetrahydrofolate reductase deficiency. Clin Neurol Neurosurg. 94, 307-10.
Calo, L. A., Pessina, A. C., 2007. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. J Hypertens. 25, 259-64.
Campbell, J. P., Alvarez, J. A., 1989. Acute arsenic intoxication. Am Fam Physician. 40, 93-7.
Carter, D. E., Aposhian, H. V., Gandolfi, A. J., 2003. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol Appl Pharmacol. 193, 309-34.
Celik, I., Gallicchio, L., Boyd, K., et al., 2008. Arsenic in drinking water and lung cancer: A systematic review. Environmental Research. 108, 48-55.
Chadzinska, M., Kolaczkowska, E., Seljelid, R., et al., 1999. Morphine modulation of peritoneal inflammation in Atlantic salmon and CB6 mice. J Leukoc Biol. 65, 590-6.
Chang, W. C., Chen, S. H., Wu, H. L., et al., 1991. Cytoprotective effect of reduced glutathione in arsenical-induced endothelial cell injury. Toxicology. 69, 101-10.
Chen, A. L., Lewis, S. P., Su, Z., et al., 1992. Superconductivity in arsenic at high pressures. Phys Rev B Condens Matter. 46, 5523-5527.
Chen, K., Chiout, P., 2001. Oral treatment of mule ducks with arsenicals for inducing fatty liver. Poult Sci. 80, 295-301.
Chen, S. C., Chen, W. C., 2008. Vascular leakage induced by exposure to arsenic via increased production of NO, hydroxyl radical and peroxynitrite. Microvasc Res. 75, 373-80.
Chen, S. C., Tsai, M. H., Wang, H. J., et al., 2004. Vascular permeability alterations induced by arsenic. Hum Exp Toxicol. 23, 1-7.
Chen, S. C., Tsai, M. H., Wang, H. J., et al., 2007. Involvement of substance P and neurogenic inflammation in arsenic-induced early vascular dysfunction. Toxicol Sci. 95, 82-8.
Chiou, H. Y., Huang, W. I., Su, C. L., et al., 1997. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 28, 1717-23.
D?朦z-Villase?瓨r, A., Burns, A. L., Hiriart, M., et al., 2007. Arsenic-induced alteration in the expression of genes related to type 2 diabetes mellitus. Toxicol Appl Pharmacol. 225, 123-133.
D?朦z-Villase?瓨r, A., Burns, A. L., Salazar, A. M., et al., 2008. Arsenite reduces insulin secretion in rat pancreatic [beta]-cells by decreasing the calcium-dependent calpain-10 proteolysis of SNAP-25. Toxicol Appl Pharmacol. 231, 291-299.
Dvorak, H. F., 2006. Discovery of vascular permeability factor (VPF). Exp Cell Res. 312, 522-526.
Engel, R. R., Hopenhayn-Rich, C., Receveur, O., et al., 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev. 16, 184-209.
Esper, R. J., Vilarino, J. O., Machado, R. A., et al., 2008. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv Cardiol. 45, 17-43.
Gazitt, Y., Akay, C., 2005. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology. 10, 205-13.
Guo, H. R., 2007. Cancer risks associated with arsenic in drinking water. Environ Health Perspect. 115, A339-40; author reply A340-1.
Hall, A. H., 2002. Chronic arsenic poisoning. Toxicol Lett. 128, 69-72.
Hayakawa, T., Kobayashi, Y., Cui, X., et al., 2005. A new metabolic pathway of arsenite: arsenic–glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Archives of Toxicology. 79, 183-191.
Hu, J., Fang, J., Dong, Y., et al., 2005. Arsenic in cancer therapy. Anticancer Drugs. 16, 119-27.
Inoue, H., Asaka, T., Nagata, N., et al., 1997. Mechanism of mustard oil-induced skin inflammation in mice. Eur J Pharmacol. 333, 231-40.
Isabella Ruocco, A. C. C., Ryuichi Shigemoto, Alfredo Ribeiro-da-Silva,, 2001. Light and electron microscopic study of the distribution of substance P-immunoreactive fibers and neurokinin-1 receptors in the skin of the rat lower lip. The Journal of Comparative Neurology. 432, 466-480.
Ishizaki, T., Uehata, M., Tamechika, I., et al., 2000. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 57, 976-83.
Izquierdo-Vega, J. A., Soto, C. A., Sanchez-Pena, L. C., et al., 2006. Diabetogenic effects and pancreatic oxidative damage in rats subchronically exposed to arsenite. Toxicol Lett. 160, 135-42.
Jancso, N., Jancso-Gabor, A., Szolcsanyi, J., 1967. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother. 31, 138-51.
Jin, L., Burnett, A. L., 2006. RhoA/Rho-kinase in erectile tissue: mechanisms of disease and therapeutic insights. Clin Sci (Lond). 110, 153-65.
Kao, Y. H., Yu, C. L., Chang, L. W., et al., 2003. Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem Res Toxicol. 16, 460-8.
Kirk, S. L., Karlik, S. J., 2003. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun. 21, 353-363.
Kumagai, Y., Sumi, D., 2007. Arsenic: Signal Transduction, Transcription Factor, and Biotransformation Involved in Cellular Response and Toxicity. Annual Review of Pharmacology and Toxicology. 47, 243-262.
Kusama, K., Nozu, F., Awai, T., et al., 2003. Deactivation of ROCK-II by Y-27632 enhances basolateral pancreatic enzyme secretion and acute pancreatitis induced by CCK analogues. Biochem Biophys Res Commun. 305, 339-44.
Larsen, G. L., Henson, P. M., 1983. Mediators of inflammation. Annu Rev Immunol. 1, 335-59.
Lee, M. Y., Jung, B. I., Chung, S. M., et al., 2003. Arsenic-induced dysfunction in relaxation of blood vessels. Environ Health Perspect. 111, 513-7.
Lee, M. Y., Lee, Y. H., Lim, K. M., et al., 2005. Inorganic arsenite potentiates vasoconstriction through calcium sensitization in vascular smooth muscle. Environ Health Perspect. 113, 1330-5.
Leung, T., Chen, X. Q., Manser, E., et al., 1996. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol. 16, 5313-27.
Liu, B., Pan, S., Dong, X., et al., 2006. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 97, 675-81.
Louis, S. M., Jamieson, A., Russell, N. J., et al., 1989. The role of substance P and calcitonin gene-related peptide in neurogenic plasma extravasation and vasodilatation in the rat. Neuroscience. 32, 581-6.
MCDONALD, D. M., 2001. Angiogenesis and Remodeling of Airway Vasculature in Chronic Inflammation. Am. J. Respir. Crit. Care Med. 164, 39S-45.
McDonald, D. M., Bowden, J. J., Baluk, P., et al., 1996. Neurogenic inflammation. A model for studying efferent actions of sensory nerves. Adv Exp Med Biol. 410, 453-62.
Nagy, J., Benjamin, L., Zeng, H., et al., 2008. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 11, 109-119.
Navas-Acien, A., Silbergeld, E. K., Streeter, R. A., et al., 2006. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ Health Perspect. 114, 641-8.
Nordstrom, D. K., 2002. PUBLIC HEALTH: Enhanced: Worldwide Occurrences of Arsenic in Ground Water. Science. 296, 2143-2145.
Pysher, M. D., Chen, Q. M., Vaillancourt, R. R., 2008. Arsenic alters vascular smooth muscle cell focal adhesion complexes leading to activation of FAK-src mediated pathways. Toxicol Appl Pharmacol. 231, 135-41.
Ren, X. D., Schwartz, M. A., 2000. Determination of GTP loading on Rho. Methods Enzymol. 325, 264-72.
Rossman, T. G., 2003. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res. 533, 37-65.
Saria, A., Hua, X., Skofitsch, G., et al., 1984. Inhibition of compound 48/80--induced vascular protein leakage by pretreatment with capsaicin and a substance P antagonist. Naunyn Schmiedebergs Arch Pharmacol. 328, 9-15.
Simeonova, P. P., Luster, M. I., 2004. Arsenic and atherosclerosis. Toxicol Appl Pharmacol. 198, 444-9.
Smith, A. H., Hopenhayn-Rich, C., Bates, M. N., et al., 1992. Cancer risks from arsenic in drinking water. Environ Health Perspect. 97, 259-67.
Soucy, N. V., Ihnat, M. A., Kamat, C. D., et al., 2003. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol Sci. 76, 271-9.
Straub, A. C., Stolz, D. B., Vin, H., et al., 2006. Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol Appl Pharmacol.
Styblo, M., Del Razo, L. M., LeCluyse, E. L., et al., 1999. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol. 12, 560-5.
Sun, H., Breslin, J. W., Zhu, J., et al., 2006. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation. 13, 237-47.
Takahashi, H., Shibuya, M., 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 109, 227-41.
Tapio, S., Grosche, B., 2006. Arsenic in the aetiology of cancer. Mutat Res. 612, 215-46.
Tesfamariam, B., DeFelice, A. F., 2007. Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol. 46, 229-37.
Touyz, R. M., Schiffrin, E. L., 2004. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol. 122, 339-52.
Tsai, M.-H., Chen, S.-C., Wang, H.-J., et al., 2005. A Mouse Model for the Study of Vascular Permeability Changes Induced by Arsenic. Toxicology Mechanisms and Methods. 15, 433 - 437.
Tseng, C. H., 2002. An overview on peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Angiology. 53, 529-37.
Tseng, C. H., 2005. Blackfoot disease and arsenic: a never-ending story. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 23, 55-74.
Tseng, C. H., Chong, C. K., Chen, C. J., et al., 1996. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis. 120, 125-33.
Tseng, W. P., 1961. Experimental studies on the influences of the antineoplastic chemotherapeutic agents on the leukocyte picture of the peripheral blood. J Formos Med Assoc. 60, 898-925.
Tseng, W. P., 1977. Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect. 19, 109-19.
Tseng, W. P., 1989. Blackfoot disease in Taiwan: a 30-year follow-up study. Angiology. 40, 547-58.
Utsunomiya, I., Yoshihashi, E., Tanabe, S., et al., 2008. Expression and localization of Kv1 potassium channels in rat dorsal and ventral spinal roots. Experimental Neurology. 210, 51-58.
van Nieuw Amerongen, G. P., Koolwijk, P., Versteilen, A., et al., 2003. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol. 23, 211-7.
Wang, C. H., Jeng, J. S., Yip, P. K., et al., 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 105, 1804-9.
Wang, S. L., Chiou, J. M., Chen, C. J., et al., 2003. Prevalence of non-insulin-dependent diabetes mellitus and related vascular diseases in southwestern arseniasis-endemic and nonendemic areas in Taiwan. Environ Health Perspect. 111, 155-59.
Weis, S. M., 2008. Vascular permeability in cardiovascular disease and cancer. Curr Opin Hematol. 15, 243-9.
Yoneda, A., Multhaupt, H. A., Couchman, J. R., 2005. The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol. 170, 443-53.
Zhao, D., Kuhnt-Moore, S., Zeng, H., et al., 2002. Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases. Biochem J. 368, 665-72.
蔡明憲, 神經性發炎在砷引起的血管傷害中所扮演的角色. 高雄醫學大學醫學研究所碩士論文, 2006.